Hyperalgesia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hyperalgesia – Drugs In Development, 2024 report and make more profitable business decisions.
Hyperalgesia is an increase in pain response. Predisposing factors include long-term opioid usage, inflammation, damage to nociceptors, damage to peripheral nerves, and psychological disorders. Treatment includes antidepressants and non-steroidal anti-inflammatory drugs (NSAIDs).
The Hyperalgesia drugs in development market research report provide comprehensive information on the therapeutics under development for Hyperalgesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hyperalgesia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 11 molecules, with 6 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hyperalgesia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hyperalgesia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hyperalgesia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Caventure Drug Discovery IncCharleston Laboratories Inc
Exodos Life Sciences Limited Partnership
Fujian Normal University
Halia Therapeutics Inc
Johns Hopkins University
Northwest University
China
Novartis AG
SATT Conectus Alsace SAS
Tulane University
University of California San Diego
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hyperalgesia reports